| abstract |
The present invention provides an oral cyclosporin composition comprising a basic encyclosporin, at least one C2-C3 alkanol solvent, a nonionic polyoxyalkylene surfactant selected from at least one polyoxyethylene alcohol and a C4-C6 ethoxylated polyol fatty acid monoester and having a molecular weight of at least 800-10,000 daltons. The compositions of the present invention are useful in immunosuppressive therapy, have high bioavailability, and can be administered in both liquid and solid capsule form. SHE |